Argon Laser Photocoagulation for Neovascular Maculopathy

Three-year Results From Randomized Clinical Trials

Executive Committee

Research output: Contribution to journalArticle

Abstract

The Macular Photocoagulation Study randomized controlled clinical trials designed to determine whether argon laser photocoagulation is effective for preventing or delaying severe visual loss in eyes with an extrafoveal choroidal neovascular membrane secondary to senile macular degeneration (Senile Macular Degeneration Study [SMDS]), ocular histoplasmosis (Ocular Histoplasmosis Study [OHS]), or idiopathic neovascularization (Idiopathic Neovascularization Study [INVS]). Eligible patients were assigned randomly to a "treatment" group or to a "no treatment" group until recruitment was terminated in 1982 (SMDS) and 1983 (OHS and INVS) because of demonstrated short-term treatment benefit. As of Aug 31, 1985, three or more years of scheduled follow-up examinations had been completed for 208 (88%) of 236 eyes in the SMDS, 203 (77%) of 262 eyes in the OHS, and 51 (76%) of 67 eyes in the INVS. The relative risk of experiencing severe loss of vision after three years in eyes initially assigned to the no treatment group in comparison with eyes assigned to the argon laser photocoagulation group was 1.4 in the SMDS (95% confidence interval [CI]: 1.1 to 1.9), 5.5 in the OHS (95% CI: 3.9 to 10.8), and 2.3 in the INVS (95% CI: 0.8 to 6.5). The beneficial effects of argon laser treatment have persisted in all three studies in spite of the fact that some eyes in the "no treatment" groups were treated later in their clinical course as a result of the evidence of early benefit. Follow-up of all patients continues so that treatment effectiveness over a five-year period can be assessed.

Original languageEnglish (US)
Pages (from-to)694-701
Number of pages8
JournalArchives of Ophthalmology
Volume104
Issue number5
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

Light Coagulation
Argon
Lasers
Randomized Controlled Trials
Histoplasmosis
Confidence Intervals
Therapeutics
Macular Degeneration, Age-Related, 2

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Argon Laser Photocoagulation for Neovascular Maculopathy : Three-year Results From Randomized Clinical Trials. / Executive Committee.

In: Archives of Ophthalmology, Vol. 104, No. 5, 1986, p. 694-701.

Research output: Contribution to journalArticle

@article{12f567995a6945ad99cf61a371c9c999,
title = "Argon Laser Photocoagulation for Neovascular Maculopathy: Three-year Results From Randomized Clinical Trials",
abstract = "The Macular Photocoagulation Study randomized controlled clinical trials designed to determine whether argon laser photocoagulation is effective for preventing or delaying severe visual loss in eyes with an extrafoveal choroidal neovascular membrane secondary to senile macular degeneration (Senile Macular Degeneration Study [SMDS]), ocular histoplasmosis (Ocular Histoplasmosis Study [OHS]), or idiopathic neovascularization (Idiopathic Neovascularization Study [INVS]). Eligible patients were assigned randomly to a {"}treatment{"} group or to a {"}no treatment{"} group until recruitment was terminated in 1982 (SMDS) and 1983 (OHS and INVS) because of demonstrated short-term treatment benefit. As of Aug 31, 1985, three or more years of scheduled follow-up examinations had been completed for 208 (88{\%}) of 236 eyes in the SMDS, 203 (77{\%}) of 262 eyes in the OHS, and 51 (76{\%}) of 67 eyes in the INVS. The relative risk of experiencing severe loss of vision after three years in eyes initially assigned to the no treatment group in comparison with eyes assigned to the argon laser photocoagulation group was 1.4 in the SMDS (95{\%} confidence interval [CI]: 1.1 to 1.9), 5.5 in the OHS (95{\%} CI: 3.9 to 10.8), and 2.3 in the INVS (95{\%} CI: 0.8 to 6.5). The beneficial effects of argon laser treatment have persisted in all three studies in spite of the fact that some eyes in the {"}no treatment{"} groups were treated later in their clinical course as a result of the evidence of early benefit. Follow-up of all patients continues so that treatment effectiveness over a five-year period can be assessed.",
author = "{Executive Committee} and Hawkins, {Barbara S} and Fine, {Stuart L.} and J. Donald and M. Gass",
year = "1986",
doi = "10.1001/archopht.1986.01050170084028",
language = "English (US)",
volume = "104",
pages = "694--701",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Argon Laser Photocoagulation for Neovascular Maculopathy

T2 - Three-year Results From Randomized Clinical Trials

AU - Executive Committee

AU - Hawkins, Barbara S

AU - Fine, Stuart L.

AU - Donald, J.

AU - Gass, M.

PY - 1986

Y1 - 1986

N2 - The Macular Photocoagulation Study randomized controlled clinical trials designed to determine whether argon laser photocoagulation is effective for preventing or delaying severe visual loss in eyes with an extrafoveal choroidal neovascular membrane secondary to senile macular degeneration (Senile Macular Degeneration Study [SMDS]), ocular histoplasmosis (Ocular Histoplasmosis Study [OHS]), or idiopathic neovascularization (Idiopathic Neovascularization Study [INVS]). Eligible patients were assigned randomly to a "treatment" group or to a "no treatment" group until recruitment was terminated in 1982 (SMDS) and 1983 (OHS and INVS) because of demonstrated short-term treatment benefit. As of Aug 31, 1985, three or more years of scheduled follow-up examinations had been completed for 208 (88%) of 236 eyes in the SMDS, 203 (77%) of 262 eyes in the OHS, and 51 (76%) of 67 eyes in the INVS. The relative risk of experiencing severe loss of vision after three years in eyes initially assigned to the no treatment group in comparison with eyes assigned to the argon laser photocoagulation group was 1.4 in the SMDS (95% confidence interval [CI]: 1.1 to 1.9), 5.5 in the OHS (95% CI: 3.9 to 10.8), and 2.3 in the INVS (95% CI: 0.8 to 6.5). The beneficial effects of argon laser treatment have persisted in all three studies in spite of the fact that some eyes in the "no treatment" groups were treated later in their clinical course as a result of the evidence of early benefit. Follow-up of all patients continues so that treatment effectiveness over a five-year period can be assessed.

AB - The Macular Photocoagulation Study randomized controlled clinical trials designed to determine whether argon laser photocoagulation is effective for preventing or delaying severe visual loss in eyes with an extrafoveal choroidal neovascular membrane secondary to senile macular degeneration (Senile Macular Degeneration Study [SMDS]), ocular histoplasmosis (Ocular Histoplasmosis Study [OHS]), or idiopathic neovascularization (Idiopathic Neovascularization Study [INVS]). Eligible patients were assigned randomly to a "treatment" group or to a "no treatment" group until recruitment was terminated in 1982 (SMDS) and 1983 (OHS and INVS) because of demonstrated short-term treatment benefit. As of Aug 31, 1985, three or more years of scheduled follow-up examinations had been completed for 208 (88%) of 236 eyes in the SMDS, 203 (77%) of 262 eyes in the OHS, and 51 (76%) of 67 eyes in the INVS. The relative risk of experiencing severe loss of vision after three years in eyes initially assigned to the no treatment group in comparison with eyes assigned to the argon laser photocoagulation group was 1.4 in the SMDS (95% confidence interval [CI]: 1.1 to 1.9), 5.5 in the OHS (95% CI: 3.9 to 10.8), and 2.3 in the INVS (95% CI: 0.8 to 6.5). The beneficial effects of argon laser treatment have persisted in all three studies in spite of the fact that some eyes in the "no treatment" groups were treated later in their clinical course as a result of the evidence of early benefit. Follow-up of all patients continues so that treatment effectiveness over a five-year period can be assessed.

UR - http://www.scopus.com/inward/record.url?scp=0022534775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022534775&partnerID=8YFLogxK

U2 - 10.1001/archopht.1986.01050170084028

DO - 10.1001/archopht.1986.01050170084028

M3 - Article

VL - 104

SP - 694

EP - 701

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 5

ER -